Boral Anthony L. 4
4 · Blueprint Medicines Corp · Filed Dec 16, 2020
Insider Transaction Report
Form 4
Boral Anthony L.
Sr. VP, Clinical Development
Transactions
- Exercise/Conversion
Common Stock
2020-12-14$15.01/sh+10,000$150,100→ 38,147 total - Sale
Common Stock
2020-12-14$118.72/sh−7,815$927,797→ 30,332 total - Sale
Common Stock
2020-12-14$117.92/sh−1,970$232,302→ 28,362 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-14−10,000→ 7,483 totalExercise: $15.01Exp: 2026-02-03→ Common Stock (10,000 underlying) - Sale
Common Stock
2020-12-14$116.75/sh−215$25,101→ 28,147 total
Footnotes (4)
- [F1]Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.32 to $119.315 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.39 to $118.30 per share.
- [F4]This option was granted on February 3, 2016. This option is fully vested as of the date hereof.